论文部分内容阅读
[目的]探索中医升阳透毒法配合干扰素治疗慢性低酶乙型肝炎的疗效。[方法]运用升阳透毒法治疗慢性低酶型乙型肝炎160例,3个月内ALT升高至100u/L以升者,随机分为“升阳透毒”组(Ⅱa组)、加用IFNα-1b(Ⅱ b组)、单用IFNα-1b组(Ⅱc组);3个月内仍属低酶者设为对照组(Ⅰ组),继续用“升阳透毒法”治疗。Ⅰ、Ⅱ组所有患者分别按各自方案治疗6个月。[结果]Ⅱa、Ⅱb、Ⅱc组在ALT复常、HBeAg/HBeAb血清转换、HBV-DNA阴转率方面均优于Ⅰ组(P<0.05);Ⅱ b、Ⅱc组明显优于Ⅰ组(P<0.05);Ⅱb、Ⅱc之间比较差异无显著性(P>0.05)。[结论]运用升阳透毒法治疗慢性低酶型乙型肝炎至ALT升高至100u/L以上,适时加用或改用干扰素继续治疗可获满意疗效。
[Objective] To explore the efficacy of traditional Chinese medicine Sun yat-sen toxemia combined with interferon in the treatment of chronic low-level hepatitis B virus. [Methods] 160 cases of chronic low-type hepatitis B were treated with Shengyang Tongdu drug. The ALT was increased to 100u / L within 3 months and then randomly divided into group Ⅱa ), Plus IFNα-1b (Ⅱ b group), IFNα-1b alone group (Ⅱc group); within 3 months is still a low enzyme was set as the control group (Ⅰ group), continue with “ Act ”treatment. All patients in group Ⅰ and Ⅱ were treated for 6 months according to their respective regimens. [Results] The levels of ALT, HBeAg / HBeAb seroconversion and HBV-DNA negative conversion rate in group Ⅱa, Ⅱb and Ⅱc were all better than those in group Ⅰ (P <0.05); Ⅱ b and Ⅱc groups were significantly better than those in group Ⅰ <0.05). There was no significant difference between Ⅱb and Ⅱc (P> 0.05). [Conclusion] The application of Shengyang Tongdu treatment of chronic low-hepatitis B to ALT increased to 100u / L or more, timely or with interferon treatment continued to obtain satisfactory results.